Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haïk, S.
Right arrow Articles by Alpérovitch, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haïk, S.
Right arrow Articles by Alpérovitch, A.
Related Collections
Right arrow Prion
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Prion disease; see Infections/prion
NEUROLOGY 2004;63:2413-2415
© 2004 American Academy of Neurology
Brief Communications

Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects

S. Haïk, MD, PhD, J. P. Brandel, MD, D. Salomon, BA, V. Sazdovitch, MD, N. Delasnerie-Lauprêtre, MD, J. L. Laplanche, PharmD, PhD, B. A. Faucheux, PhD, C. Soubrié, MD, E. Boher, PharmD, C. Belorgey, MD, J. J. Hauw, MD and A. Alpérovitch, MD

From Raymond Escourolle Neuropathology Laboratory (Drs. Haïk, Sazdovitch, Faucheux, and Hauw), French National Reference Center for Creutzfeldt–Jakob Diseases (Drs. Haïk and Brandel), INSERM U360 (Drs. Haïk, Brandel, Sazdovitch, Delasnerie-Lauprêtre, Faucheux, Hauw, and Alpérovitch, D. Salomon), Pharmacovigilance Center, Pharmacology Laboratory (Dr. Soubrié), Salpêtrière Hospital, and Central Biochemistry Laboratory (Dr. Laplanche), Lariboisière Hospital, Paris, and AFSSAPS (Drs. Belorgey and Boher), Saint-Denis, France.

Address correspondence and reprint requests to Dr. S. Haïk, Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpêtrière Hospital, 47, bd de l’Hôpital, 75651 Paris Cedex 13, France; e-mail: haik{at}chups.jussieu.fr

Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt–Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.

Received June 30, 2004. Accepted in final form August 13, 2004.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
S. Haik, D. Galanaud, M. G. Linguraru, K. Peoc'h, N. Privat, B. A. Faucheux, N. Ayache, J.-J. Hauw, D. Dormont, and J.-P. Brandel
In Vivo Detection of Thalamic Gliosis: A Pathoradiologic Demonstration in Familial Fatal Insomnia
Arch Neurol, April 1, 2008; 65(4): 545 - 549.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Cronier, V. Beringue, A. Bellon, J.-M. Peyrin, and H. Laude
Prion Strain- and Species-Dependent Effects of Antiprion Molecules in Primary Neuronal Cultures
J. Virol., December 15, 2007; 81(24): 13794 - 13800.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Webb, T. Lekishvili, C. Loeschner, S. Sellarajah, F. Prelli, T. Wisniewski, I. H. Gilbert, and D. R. Brown
Mechanistic Insights into the Cure of Prion Disease by Novel Antiprion Compounds
J. Virol., October 1, 2007; 81(19): 10729 - 10741.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
C. Korth and P. J. Peters
Emerging pharmacotherapies for creutzfeldt-jakob disease.
Arch Neurol, April 1, 2006; 63(4): 497 - 501.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Benito-Leon, S. Haik, and J.-P. Brandel
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects
Neurology, May 24, 2005; 64(10): 1824 - 1824.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects
Julián Benito-León
Neurology Online, 31 Jan 2005 [Full text]
Reply to Benito-León
Stéphane Haïk, et al.
Neurology Online, 31 Jan 2005 [Full text]